Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019

Abstract Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID‐19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID‐19 treatments. Common unintended nontherapeutic target effects of COVID‐19 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P‐glycoprotein inhibition. Drug‐drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID‐19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID‐19 patients with concomitant atrial fibrillation.

Download Full-text

Utilisation of Robotic Navigation Systems in the Treatment of Atrial Fibrillation

European Cardiology Review ◽

10.15420/ecr.2010.6.3.60 ◽

2010 ◽

Vol 6 (3) ◽

pp. 60

Author(s):

Richard Schilling ◽

Keyword(s):

Atrial Fibrillation ◽

Catheter Ablation ◽

Navigation System ◽

Antiarrhythmic Drugs ◽

Rhythm Control ◽

Navigation Systems ◽

Robotic Navigation ◽

Increased Risk ◽

Common Strategy ◽

Catheter Navigation

Atrial fibrillation (AF) is linked to an increased risk of adverse cardiovascular events. While rhythm control with antiarrhythmic drugs (AADs) is a common strategy for managing patients with AF, catheter ablation may be a more efficacious and safer alternative to AADs for sinus rhythm control. Conventional catheter ablation has been associated with challenges during the arrhythmia mapping and ablation stages; however, the introduction of two remote catheter navigation systems (a robotic and a magnetic navigation system) may potentially overcome these challenges. Initial clinical experience with the robotic navigation system suggests that it offers similar procedural times, efficacy and safety to conventional manual ablation. Furthermore, it has been associated with reduced fluoroscopy exposure to the patient and the operator as well as a shorter fluoroscopy time compared with conventional catheter ablation. In the future, the remote navigation systems may become routinely used for complex catheter ablation procedures.

Download Full-text

Ion Channel Remodelling in Atrial Fibrillation

European Cardiology Review ◽

10.15420/ecr.2011.7.2.97 ◽

2011 ◽

Vol 7 (2) ◽

pp. 97 ◽

Cited By ~ 6

Author(s):

Niels Voigt ◽

Dobromir Dobrev ◽

◽

Keyword(s):

Atrial Fibrillation ◽

Ion Channel ◽

Antiarrhythmic Drugs ◽

Current Knowledge ◽

Bleeding Complications ◽

Large Size ◽

Cardiovascular Morbidity And Mortality ◽

Number Of Patients ◽

Life Threatening ◽

Underlying Mechanisms

Atrial fibrillation (AF) is the most common arrhythmia and is associated with substantial cardiovascular morbidity and mortality, with stroke being the most critical complication. Present drugs used for the therapy of AF (antiarrhythmics and anticoagulants) have major limitations, including incomplete efficacy, risks of life-threatening proarrhythmic events and bleeding complications. Non-pharmacological ablation procedures are efficient and apparently safe, but the very large size of the patient population allows ablation treatment of only a small number of patients. These limitations largely result from limited knowledge about the underlying mechanisms of AF and there is a hope that a better understanding of the molecular basis of AF may lead to the discovery of safer and more effective therapeutic targets. This article reviews the current knowledge about AF-related ion-channel remodelling and discusses how these alterations might affect the efficacy of antiarrhythmic drugs.

Download Full-text